Abbott Laboratories $ABT Shares Sold by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC decreased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 4.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 120,720 shares of the healthcare product maker’s stock after selling 5,222 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Abbott Laboratories were worth $15,125,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Cloud Capital Management LLC purchased a new stake in Abbott Laboratories during the 3rd quarter valued at about $29,000. Guerra Advisors Inc purchased a new position in Abbott Laboratories in the 3rd quarter worth approximately $31,000. Delos Wealth Advisors LLC acquired a new position in shares of Abbott Laboratories during the 2nd quarter worth approximately $32,000. Bridge Generations Wealth Management LLC purchased a new stake in shares of Abbott Laboratories in the third quarter valued at approximately $33,000. Finally, Copia Wealth Management acquired a new stake in shares of Abbott Laboratories in the third quarter valued at approximately $38,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Abbott Laboratories

In other news, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the completion of the transaction, the vice president owned 24,628 shares of the company’s stock, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president owned 39,164 shares of the company’s stock, valued at $4,526,575.12. This trade represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 3,055 shares of company stock valued at $353,097. Corporate insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on ABT shares. Piper Sandler lowered their price objective on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research note on Friday, January 23rd. Raymond James Financial reduced their price target on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Barclays lowered their price target on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a research report on Monday, February 2nd. BTIG Research cut their price objective on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Finally, Weiss Ratings downgraded shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $136.16.

Abbott Laboratories Stock Down 0.4%

NYSE:ABT opened at $104.12 on Friday. Abbott Laboratories has a 52 week low of $102.41 and a 52 week high of $139.06. The stock’s fifty day moving average is $110.82 and its two-hundred day moving average is $122.06. The stock has a market capitalization of $181.35 billion, a price-to-earnings ratio of 27.99, a price-to-earnings-growth ratio of 1.65 and a beta of 0.74. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same period in the previous year, the firm posted $1.34 earnings per share. The company’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio is 67.74%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.